文献速递乳房整形与再造美容整形

1501例美容乳房手术队列中BIA-ALCL的流行病学

BIA-ALCL Epidemiology in an Aesthetic Breast Surgery Cohort of 1501 Patients.
PubMed 文献 · Aesthet Surg J · 2023-01-01

该前瞻性队列观察研究纳入2006至2016年间接受美容性乳房增大术的1501例患者,记录包括BIA-ALCL在内的植入物相关并发症。BIA-ALCL患病率为1:300例患者,植入物特异性患病率为6.9例/1000人/Allergan BIOCELL装置和1.3例/1000人/Mentor Siltex装置,发病率为1.07例/1000女性/年。作者认为在美容患者队列中BIA-ALCL发生率高于既往报告,尤其见于粗面装置。

要点

  • 美容乳房增大队列中BIA-ALCL患病率为1:300例患者。
  • Allergan BIOCELL装置植入物特异性患病率为6.9例/1000人。
  • Mentor Siltex装置植入物特异性患病率为1.3例/1000人。

核心结论

  • 在美容患者队列中,BIA-ALCL的发生率高于既往报告,尤其见于粗面装置。
  • 鉴于重建队列与美容队列的发病率相似,其均匀分布可能源于美容组随访较差和认知较低导致的漏报。
  • 肿瘤队列中的遗传易感性可能比发病率更多地影响早期发病。
  • 准确随访的重要性得到确认。
  • 分层风险分析可在患者咨询中指导外科医生关于预防性取出植入物的决策。

研究设计与样本

  • 前瞻性队列观察研究,纳入2006年至2016年间接受美容性乳房增大术的1501例患者。
  • 记录包括BIA-ALCL在内的任何植入物相关并发症,并通过临床、病理和外部记录数据交叉核对识别病例。
  • 计算患病率、植入物特异性患病率、发病率、无事件时间和Kaplan-Meier生存估计。

主要发现

  • 除2例患者外,其余患者均双侧接受粗面或微面装置。
  • 平均随访3.2年(1个月至16.4年)。
  • 调查了5例BIA-ALCL病例。
  • 患病率为1:300例患者;植入物特异性患病率为6.9例/1000人/Allergan BIOCELL装置和1.3例/1000人/Mentor Siltex装置;发病率为1.07例/1000女性/年。
  • 平均(SD)无事件时间为9.2年。

临床怎么用

  • 作者认为准确随访的重要性得到确认。
  • 作者认为分层风险分析可在患者咨询中指导外科医生关于预防性取出植入物的决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidemiologic studies on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) currently estimate the risk between 1:300 and 1:30,000, assessed mainly in large breast reconstruction populations. OBJECTIVES: The aim of the study was to assess BIA-ALCL epidemiology in a cohort of patients who have received textured implants for cosmetic indications. METHODS: In a prospective cohort observational study, 1501 patients who received a cosmetic breast augmentation between 2006 and 2016 were monitored, recording any implant-related complications, including BIA-ALCL. Cross-checking of clinical, pathology, and external records data identified cases. Prevalence, implant-specific prevalence (I-SP), incidence rate (IR), event-free time (EFT), and the Kaplan-Meier survival estimate were calculated. RESULTS: All but 2 patients received macrotextured or microtextured devices bilaterally. Mean follow-up was 3.2 years (1 months to 16.4 years). Five BIA-ALCL cases were investigated. Prevalence was 1:300 patients; I-SP was 6.9 cases/1000 individuals/Allergan BIOCELL devices and 1.3 cases/1000 individuals/Mentor Siltex devices; and IR was 1.07 cases/1000 females/year. Mean (SD) EFT was 9.2 years. CONCLUSIONS: When using a denominator based on a cohort of cosmetic patients, BIA-ALCL occurrence is higher than previously reported, particularly with macrotextured devices. Given the similar IRs in reconstructive and cosmetic cohorts, their even distribution could be consequent to underreporting due to poorer follow-up and lower awareness in the latter group. The genetic predisposition in the oncologic cohort reasonably affects the early onset more than the IR. The importance of accurate follow-up is confirmed. Stratification risks analysis can guide surgeons during patient counseling regarding the decision for prophylactic explantation.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Kolasiński J, Sorotos M, Firmani G, et al. BIA-ALCL Epidemiology in an Aesthetic Breast Surgery Cohort of 1501 Patients. Aesthet Surg J. 2023. PMID: 37289985. doi:10.1093/asj/sjad181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。